Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Study sponsor: Brainstorm-Cell Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-11-01Estimated
Enrollment · participants200Estimated
Source updated2025-05-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.